House Appropriators Go Low On FDA's Budget
Executive Summary
Appropriation set for CFSAN and ORA’s related field activities is $1.16bn, up slightly from the FY2021 level of $1.1bn, and for CDER and ORA’s related activities is $2.1bn, up $100m from current funding.
You may also be interested in...
In Second Term At Helm, Would Califf Steer US FDA On Supplement Market Regulation Changes?
CRN and NPA are receptive to former FDA Commissioner Robert Califf’s potential return to the post. NPA says his previous comments on FDA’s authority is a good sign he may help act on supplement industry issues stalled within the agency in recent years.
US FDA Does FSMA User Fee Math, Not Collection
Including fees was key to Congress passing FSMA more than a decade ago and FDA had industry support asking for fees. But FDA calculations for FY2022 user fees act continue to add up to not collecting fees for facility re-inspections and recall enforcement.
US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements
Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.